283 related articles for article (PubMed ID: 31539577)
21. A therapeutic strategy of parthenolide in improving imiquimod-induced psoriasis-like skin inflammation targeting IL-36/NETs through skin transdermal therapeutic system.
Zhan ZY; Zhang ZH; Sun RH; Wu YL; Nan JX; Lian LH
Int Immunopharmacol; 2024 Apr; 131():111824. PubMed ID: 38461633
[TBL] [Abstract][Full Text] [Related]
22. Interplay between CXCR2 and BLT1 facilitates neutrophil infiltration and resultant keratinocyte activation in a murine model of imiquimod-induced psoriasis.
Sumida H; Yanagida K; Kita Y; Abe J; Matsushima K; Nakamura M; Ishii S; Sato S; Shimizu T
J Immunol; 2014 May; 192(9):4361-9. PubMed ID: 24663678
[TBL] [Abstract][Full Text] [Related]
23. Small interfering RNA targeting of keratin 17 reduces inflammation in imiquimod-induced psoriasis-like dermatitis.
Xiao CY; Zhu ZL; Zhang C; Fu M; Qiao HJ; Wang G; Dang EL
Chin Med J (Engl); 2020 Nov; 133(24):2910-2918. PubMed ID: 33237695
[TBL] [Abstract][Full Text] [Related]
24. Garcinia Multiflora Inhibits FPR1-Mediated Neutrophil Activation and Protects Against Acute Lung Injury.
Tsai YF; Yang SC; Chang WY; Chen JJ; Chen CY; Chang SH; Hwang TL
Cell Physiol Biochem; 2018; 51(6):2776-2793. PubMed ID: 30562761
[TBL] [Abstract][Full Text] [Related]
25. Hesperidin inhibits keratinocyte proliferation and imiquimod-induced psoriasis-like dermatitis via the IRS-1/ERK1/2 pathway.
Li X; Xie X; Zhang L; Meng Y; Li N; Wang M; Zhai C; Liu Z; Di T; Zhang L; Li P
Life Sci; 2019 Feb; 219():311-321. PubMed ID: 30658103
[TBL] [Abstract][Full Text] [Related]
26. Anti-Angiogenic Efficacy of PSORI-CM02 and the Associated Mechanism in Psoriasis
Lu Y; Yang Y; Zhang J; Zhang H; Ma C; Tang X; Wu J; Li L; Wei J; Chen H; Lu C; Han L
Front Immunol; 2021; 12():649591. PubMed ID: 33995368
[TBL] [Abstract][Full Text] [Related]
27. The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice.
Geraghty NJ; Mansfield KJ; Fuller SJ; Watson D; Sluyter R
Purinergic Signal; 2017 Dec; 13(4):405-415. PubMed ID: 28597172
[TBL] [Abstract][Full Text] [Related]
28. D-Pinitol Ameliorates Imiquimod-Induced PsoriasisLike Skin Inflammation in a Mouse Model via the NF-κB Pathway.
Ma J; Feng S; Ai D; Liu Y; Yang X
J Environ Pathol Toxicol Oncol; 2019; 38(3):285-295. PubMed ID: 31679314
[TBL] [Abstract][Full Text] [Related]
29. Protective effects of ambroxol in psoriasis like skin inflammation: Exploration of possible mechanisms.
Sunkari S; Thatikonda S; Pooladanda V; Challa VS; Godugu C
Int Immunopharmacol; 2019 Jun; 71():301-312. PubMed ID: 30933843
[TBL] [Abstract][Full Text] [Related]
30. Topical Application of BMS-509744, a Selective Inhibitor of Interleukin-2-Inducible T Cell Kinase, Ameliorates Imiquimod-Induced Skin Inflammation in Mice.
Otake S; Otsubaki T; Uesato N; Ueda Y; Murayama T; Hayashi M
Biol Pharm Bull; 2021 Apr; 44(4):528-534. PubMed ID: 33473072
[TBL] [Abstract][Full Text] [Related]
31. Effects of Human Mesenchymal Stem Cells Transduced with Superoxide Dismutase on Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice.
Sah SK; Park KH; Yun CO; Kang KS; Kim TY
Antioxid Redox Signal; 2016 Feb; 24(5):233-48. PubMed ID: 26462411
[TBL] [Abstract][Full Text] [Related]
32. Luteolin attenuates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via suppression of inflammation response.
Zhou W; Hu M; Zang X; Liu Q; Du J; Hu J; Zhang L; Du Z; Xiang Z
Biomed Pharmacother; 2020 Nov; 131():110696. PubMed ID: 32920513
[TBL] [Abstract][Full Text] [Related]
33. Neutrophil extracellular traps are induced in a psoriasis model of interleukin-36 receptor antagonist-deficient mice.
Watanabe S; Iwata Y; Fukushima H; Saito K; Tanaka Y; Hasegawa Y; Akiyama M; Sugiura K
Sci Rep; 2020 Nov; 10(1):20149. PubMed ID: 33214582
[TBL] [Abstract][Full Text] [Related]
34. Topical administration of nanocarrier miRNA-210 antisense ameliorates imiquimod-induced psoriasis-like dermatitis in mice.
Feng H; Wu R; Zhang S; Kong Y; Liu Z; Wu H; Wang H; Su Y; Zhao M; Lu Q
J Dermatol; 2020 Feb; 47(2):147-154. PubMed ID: 31773789
[TBL] [Abstract][Full Text] [Related]
35. Ferulic acid altered IL-17A/IL-17RA interaction and protected against imiquimod-induced psoriasis-like skin injury in mice.
Lo HY; Li CC; Cheng HM; Liu IC; Ho TY; Hsiang CY
Food Chem Toxicol; 2019 Jul; 129():365-375. PubMed ID: 31054998
[TBL] [Abstract][Full Text] [Related]
36. Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions.
Lin CY; Hsu CY; Elzoghby AO; Alalaiwe A; Hwang TL; Fang JY
Acta Biomater; 2019 May; 90():350-361. PubMed ID: 30951898
[TBL] [Abstract][Full Text] [Related]
37. Quercetin ameliorates imiquimod-induced psoriasis-like skin inflammation in mice via the NF-κB pathway.
Chen H; Lu C; Liu H; Wang M; Zhao H; Yan Y; Han L
Int Immunopharmacol; 2017 Jul; 48():110-117. PubMed ID: 28499194
[TBL] [Abstract][Full Text] [Related]
38. Ameliorative effects of a fusion protein dual targeting interleukin 17A and tumor necrosis factor α on imiquimod-induced psoriasis in mice.
Liu Z; Liu H; Xu P; Yin Q; Wang Y; Opoku YK; Yang J; Song L; Sun X; Zhang T; Yu D; Wang X; Ren G; Li D
Biomed Pharmacother; 2018 Dec; 108():1425-1434. PubMed ID: 30372845
[TBL] [Abstract][Full Text] [Related]
39. Ginsenoside compound K ameliorates imiquimod-induced psoriasis-like dermatitis through inhibiting REG3A/RegIIIγ expression in keratinocytes.
Fan H; Wang Y; Zhang X; Chen J; Zhou Q; Yu Z; Chen Y; Chen Z; Gu J; Shi Y
Biochem Biophys Res Commun; 2019 Aug; 515(4):665-671. PubMed ID: 31182284
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic efficacy and mechanism action of Si Cao formula in the treatment of psoriasis: A pilot clinical investigation and animal validation.
Wu X; Zheng Q; Shen F; Song J; Luo Y; Fei X; Jiang W; Xie S; Ma X; Kuai L; Wang R; Ding X; Li M; Luo Y; Li B
J Ethnopharmacol; 2024 Apr; 323():117662. PubMed ID: 38160866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
